Patritumab Deruxtecan (Genetical Recombination)



Patritumab Deruxtecan is an antibody-drug-conjugate (molecular weight: ca. 158,000) consisting of Deruxtecan ((3RS)-1-[(10S)-10-benzyl-1-{[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]amino}-1,6,9,12,15,18-hexaoxo-3-oxa-5,8,11,14,17-pentaazatricosan-23-yl]-2,5-dioxopyrrolidin-3-yl group (C₅₂H₅₇FN₉O₁₃; molecular weight: 1,035.06)), which is composed of camptothecin derivative and linker, attached to an average of 8 Cys residues of a recombinant monoclonal antibody. The antibody moiety is a recombinant human IgG1 monoclonal antibody against a human epidermal growth factor receptor type 3 (HER3) and produced in Chinese hamster ovary cells. The protein moiety is a glycoprotein (molecular weight: ca. 150,000) composed of 2 H-chains (γ1-chains) consisting of 447 amino acid residues each and 2 L-chains (κ-chains) consisting of 220 amino acid residues each.

[2227102-46-5]